|
|
|
Volumn 7, Issue 10, 2004, Pages 935-939
|
|
Ralfinamide Newron Pharmaceuticals
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTICONVULSIVE AGENT;
ANTIDEPRESSANT AGENT;
ANTIMIGRAINE AGENT;
ANTIPARKINSON AGENT;
CARBAMAZEPINE;
DIAZEPAM;
HYPNOTIC AGENT;
LAMOTRIGINE;
MILACEMIDE;
MONOAMINE OXIDASE INHIBITOR;
NEUROPROTECTIVE AGENT;
PHENYTOIN;
PROPIONAMIDE DERIVATIVE;
RALFINAMIDE;
SAFINAMIDE;
SODIUM CHANNEL BLOCKING AGENT;
VALPROIC ACID;
ANALGESIA;
ANTICONVULSANT ACTIVITY;
ARTICLE;
ATAXIA;
BINDING AFFINITY;
CARDIOVASCULAR DISEASE;
CLINICAL TRIAL;
DRUG ABSORPTION;
DRUG CLASSIFICATION;
DRUG CONTRAINDICATION;
DRUG HALF LIFE;
DRUG METABOLISM;
DRUG POTENCY;
DRUG SAFETY;
DRUG STRUCTURE;
DRUG SYNTHESIS;
DRUG TOLERABILITY;
ENZYME INHIBITION;
FOOD DRUG INTERACTION;
HUMAN;
MEDICAL LITERATURE;
MOTOR DYSFUNCTION;
MOUSE;
NEUROPATHIC PAIN;
NONHUMAN;
PATENT;
PATHOPHYSIOLOGY;
RAT;
STRUCTURE ACTIVITY RELATION;
STRUCTURE ANALYSIS;
TOXICITY TESTING;
TREATMENT PLANNING;
CLINICAL TRIALS, PHASE I;
CLINICAL TRIALS, PHASE II;
FLUOROBENZENES;
HUMANS;
PAIN;
PERIPHERAL NERVOUS SYSTEM DISEASES;
SODIUM CHANNEL BLOCKERS;
STRUCTURE-ACTIVITY RELATIONSHIP;
|
|
EID: 7244247251
PISSN: 13697056
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (15)
|
|
References (0)
|
